Spinal muscular atrophy (SMA) therapy Spinraza has been a key earner for Biogen in recent years, but with sales now heading into reverse, the company is looking to extend its franchise.

The announcement was made by Stephanie Fradette, Pharm.D., Head of the Neuromuscular Development Unit at Biogen, who expressed gratitude to the SMA community for their support. The DEVOTE study ...

These conditions do not apply, according to AveXis, as Biogen’s Spinraza (nusinersen ... is no adequate treatment available. For this SMA population there is an adequate treatment available ...

Biogen enhances its portfolio and margins amidst market challenges and competition. Click here to find out why BIIB stock is a Hold.

Biogen, Inc. is a biopharmaceutical company ... SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis.

Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and ...

Children with SMA in the U.K. can switch treatments based on practical needs and preferences without unexpected disease ...

Biogen Inc. (Nasdaq: BIIB ... symptomatic infants with spinal muscular atrophy (SMA). The investigational higher dose regimen of nusinersen comprises a more rapid loading regimen, two 50 mg ...

Pharm.D., Head of the Neuromuscular Development Unit at Biogen. “This milestone reflects our steadfast commitment to advance treatment options for individuals with SMA, and we expect that this ...